

Use of Xylazine/Ketamine or Medetomidine Combined with Either Ketamine, Ketamine/Butorphanol, or Ketamine/Telazol for Immobilization of White-Tailed Deer (*Odocoileus Virginianus*)

¹Lisa I. Muller, ²David A. Osborn, ³Edward C. Ramsay, ⁴Tom Doherty,
²Brad F. Miller, ²Robert J. Warren and ²Karl V. Miller

¹Department of Forestry, Wildlife and Fisheries, University of Tennessee,
 274 Ellington Hall, Knoxville, TN 37996, USA

²Warnell School of Forest Resources, University of Georgia, Athens, GA 30602, USA

³Department of Small Animal Clinical Sciences,

⁴Department of Large Animal Medicine, College of Veterinary Medicine,
 University of Tennessee, Knoxville, TN 37996-4544, USA

Abstract: We immobilized 18 captive, adult, female white-tailed deer (*Odocoileus virginianus*) with a combination of either 1) xylazine/ketamine (XK; 1.6+0.1 mg kg⁻¹ xylazine and 7.8+0.3 mg kg⁻¹ ketamine antagonized with 2.1+0.1 mg kg⁻¹ tolazoline), 2) Medetomidine/Ketamine (MK; 0.075+0.01 mg kg⁻¹ medetomidine and 2.1+0.2 mg kg⁻¹ ketamine antagonized with 0.37+0.0 mg kg⁻¹ atipamezole), 3) Medetomidine/Ketamine/Butorphanol (MKB; 0.072+0.01 mg kg⁻¹ medetomidine, 2.1+0.2 mg kg⁻¹ ketamine and 0.1+ 0.0 mg kg⁻¹ butorphanol antagonized with 0.36+0.0 mg kg⁻¹ atipamezole and 10.3+1.2 mg kg⁻¹ naltrexone), 4) Medetomidine/Ketamine/Tiletamine-zolazepam-A (MKT-A; 0.063+0.0 mg kg⁻¹ medetomidine, 0.9+0.1 mg kg⁻¹ ketamine and 2.0+0.1 mg kg⁻¹ tiletamine-zolazepam antagonized with 0.31+0.0 mg kg⁻¹ atipamezole), or 5) Medetomidine/Ketamine/Tiletamine-zolazepam-B (MKT-B; 0.067+0.0 mg kg⁻¹ medetomidine, 1.4+0.1 mg kg⁻¹ ketamine and 1.1+0.1 mg kg⁻¹ tiletamine-zolazepam antagonized with 0.34+0.0 mg kg⁻¹ atipamezole). We measured times from injection to first effect, sternal recumbency and lateral recumbency. We measured SpO₂, heart rate, respiratory rate and body temperature of each deer at 20 and 40 min after lateral recumbency. Forty-five minutes after lateral recumbency, deer were given appropriate antagonist drugs (half i.v., half i.m.). All drug combinations except the XK dose produced lateral recumbency in the deer. Hyperthermia occurred in the XK, MKB and MK groups. The MKT-A and MKT-B treatments resulted in acceptable physiological parameters, rapid induction and quick recovery. Combining ketamine (for a relatively shorter recovery time), tiletamine-zolazepam (for rapid induction) and medetomidine (for synergistic effects and increased relaxation) may optimize induction and recovery times in white-tailed deer.

Key words: Butorphanol, ketamine, medetomidine, *Odocoileus virginianus*, tiletamine-zolazepam, white-tailed deer

INTRODUCTION

Capture of white-tailed deer (*Odocoileus virginianus*) is greatly facilitated by the use of potent immobilizing drugs. The characteristics of the ideal capture drug have been described as safe, short induction time, wide therapeutic index, no long-term effects, small volume for darting and reversibility (Nielson, 1999; Kreeger *et al.*, 2002; Miller *et al.*, 2003). However, previously evaluated

drug combinations require compromises among rapid induction and recovery times or other undesirable characteristics.

Xylazine plus Ketamine (XK) is commonly used for immobilization of white-tailed deer (Kreeger *et al.*, 2002). However, shorter flight distances were found after darting deer with a combination of xylazine and tiletamine-zolazepam (XT) compared to XK (Kilpatrick and Spohr, 1999). Tiletamine/zolazepam combines a dissociative

anesthetic with a benzodiazepine tranquilizer. The main disadvantage of XT is the relatively long recovery times because the longer duration of action of tiletamine/zolazepam compared to ketamine (Miller *et al.*, 2004). There is no antagonist available for the dissociative drugs and the use of different α_2 antagonists (yohimbine, atipamezole, or tolazoline) did not affect the duration of sedation in white-tailed deer immobilized with XT (Miller *et al.*, 2004). Additionally, flumazenil was not an effective antagonist for the zolazepam (Miller *et al.*, 2004).

α_2 -adrenoceptor agonists (e.g., xylazine and medetomidine) provide sedation, analgesia and muscle relaxation (Plumb, 2002). Medetomidine has 10 times the affinity for α_2 versus α_1 receptors and greater potency than xylazine (Kreeger *et al.*, 2002; Plumb, 2002). The greater receptor specificity and potency of medetomidine can lead to a reduction in the dose of dissociative agents required for immobilization and may make this drug a better choice for use with dissociative anesthetics in many species. Additionally, the antagonist, atipamezole, quickly reverses α_2 -agonists and has a high specificity for medetomidine (Plumb *et al.*, 2002).

Medetomidine alone provides effective sedation and immobilization for a variety of wildlife species including reindeer (*Rangifer tarandus*) and red deer (*Cervus elaphus*) (Jalanka and Roeken, 1990). However, variation in quality and depth of sedation are often seen and may be attributed to individual animal, species-specific or dose-dependent differences (Kumar, 1994). Ketamine or tiletamine-zolazepam are often combined with medetomidine to ensure more consistent immobilization and human safety (Jalanka and Roeken, 1990; Fernandez *et al.*, 2000). The benzodiazepine, zolazepam, causes muscle relaxation and likely contributes to the relatively rapid induction and longer duration of XT effectiveness (Kumar *et al.*, 2006), compared to XK. Tiletamine is quickly cleared from the body and has lower peak concentrations in the blood compared to zolazepam (Kumar *et al.*, 2006). Adding opioid analgesics such as butorphanol to medetomidine plus ketamine or tiletamine/zolazepam may further shorten induction times. Greater muscle relaxation and deeper sedation was found in ring-tailed lemurs (*Lemur catta*) when combining butorphanol with medetomidine (Williams *et al.*, 2003). Medetomidine/ketamine/butorphanol has been used successfully in Thomson's gazelles (*Gazella thomsoni*) (Chittick *et al.*, 2001).

In this study, we evaluated the effectiveness of XK and medetomidine combined with ketamine, ketamine/butorphanol, or ketamine/tiletamine-zolazepam for immobilizing captive white-tailed deer.

MATERIALS AND METHODS

All immobilizations were conducted with captive deer at the University of Georgia Daniel B. Warnell School of Forest Resources Whitehall Deer Research Facility (33°53'N, 83°21'W). Research protocols were reviewed and approved by the University of Tennessee and University of Georgia Animal Care and Use Committees (UT-ACUC 1431; UGA-ACUC A2005-10202-0).

We conducted trials during 11-13 April 2005 on 18 adult female deer (ages 3-12+ yr) randomly assigned to treatment group. The does were housed in outdoor pens with fertile bucks during the previous fall and winter (Miller *et al.*, 2004). At 16-24 h before drug treatments, we moved them to individual 3×6-m barn stalls. We randomly selected four females and weighed them to the nearest kg in the squeeze chute to determine a standardized dosage rate to use for all deer (mean body weight = 54 kg). Deer were not fed for 12-16 h before treatments to minimize risk of regurgitation during immobilization. To minimize the risk of thermal stress during immobilization, we administered treatments during 0700-1200 h. No adverse effects were reported on pregnancy or neonatal survival in white-tailed deer immobilized with XK during pregnancy (from December to May, with mean parturition date of 8 June) (Delgiudice *et al.*, 1986). Therefore, we expected no drug-related complications when our females were treated at 4-5 mo of gestation. However, to monitor potential treatment effects on fawning, we observed each female daily during May-July 2005.

Our drug trials included xylazine (100 mg mL⁻¹, Wildlife Pharmaceuticals, Inc., Fort Collins, Colorado 80522, USA), medetomidine (20 mg mL⁻¹ medetomidine hydrochloride, Wildlife Pharmaceuticals), ketamine (100 mg mL⁻¹ Ketaset®, Fort Dodge Animal Health, Fort Dodge, Iowa 50501, USA), butorphanol (10 mg mL⁻¹ Torbugesic®, Fort Dodge Animal Health), tiletamine/zolazepam (50 mg mL⁻¹ tiletamine and 50 mg mL⁻¹ zolazepam; 100 mg mL⁻¹ total of Telazol®, Fort Dodge Animal Health), atipamezole (5.0 mg mL⁻¹ Antisedan®, Pfizer Animal Health, Exton, Pennsylvania 19341, USA), naltrexone (50 mg mL⁻¹, Wildlife Pharmaceuticals) and tolazoline (100 mg mL⁻¹ Tolazine®, Lloyd Laboratories, Shenandoah, Iowa 51601, USA).

Drug dosage for a 54 kg deer was based on recommendations by Kreeger *et al.* (2002) for non-excited deer (due to relative adaptation to the facility and handling) unless otherwise noted. All Treatments included Xylazine/Ketamine (XK; 1.5 mg kg⁻¹ xylazine and 7.5 mg kg⁻¹ ketamine antagonized with 2.0 mg kg⁻¹ tolazoline), Medetomidine/Ketamine (MK; 0.07 mg kg⁻¹ medetomidine and 2.0 mg kg⁻¹ ketamine antagonized with

0.35 mg kg⁻¹ atipamezole), Medetomidine/ Ketamine/ Butorphanol (MKB; 0.07 mg kg⁻¹ medetomidine, 2.0 mg kg⁻¹ ketamine and 0.1 mg kg⁻¹ butorphanol, antagonized with 0.35 mg kg⁻¹ atipamezole and 10 mg kg⁻¹ naltrexone dose), Medetomidine/Ketamine/Tiletamine-zolazepam-A (MKT-A; 0.07 mg kg⁻¹ medetomidine, 1.0 mg kg⁻¹ ketamine and 2.2 mg kg⁻¹ tiletamine-zolazepam antagonized with 0.35 mg kg⁻¹ atipamezole), Medetomidine/Ketamine/tiletamine-zolazepam-B (MKT-B; 0.07 mg kg⁻¹ medetomidine, 1.5 mg kg⁻¹ ketamine and 1.1 mg kg⁻¹ tiletamine-zolazepam antagonized with 0.35 mg kg⁻¹ atipamezole).

We restrained each deer in a squeeze chute and administered drug treatments by i.m. injection in the left hindquarter. After injection, deer were released into a 15x20-m observation pen. One observer recorded time to first noticeable drug effect, sternal recumbency and lateral recumbency. Once recumbent, each deer was weighed (for determination of exact dose administered) and carried to an individual stall, treated with ophthalmic ocular lubrication (Paralube®; Pharnadern, Mellville, New York 11747, USA) to prevent corneal drying, eyes covered with a masked and held in a sternal position. At 20 and 40 min. after lateral recumbency, we recorded SpO₂ (pulse oximeter, Ohmeda Biox 3700, Ohmeda, Louisville, Colorado 80027, USA; probe placed on tongue), heart rate (determined by auscultation or from pulse oximeter), respiration rate (observed by thoracic movements) and rectal temperature. About 45 min. after lateral recumbency, deer were given the antagonists (half i.v. and half i.m.). We recorded time from antagonist administration to head

up and standing for each deer. Starting at 30 min after antagonist injection, we recorded a sedation score which ranged from 0-5 (Miller *et al.*, 2004) for each deer every 30 min for 5 h. The score was assessed as follows: lateral recumbency with no sign of reversal (5), lateral recumbency, unable to maintain the head upright and sensory movement of eyes or ears (4), unable to stand, disoriented and unsteady, but able to hold head erect (3), standing with moderate ataxia, spread stance, with head lowered occasionally (2), standing with minimal sedation characterized by lowered eyelids (1), no sign of sedation (0).

Statistical analysis was performed with SAS (SAS Institute, Cary, North Carolina 27513, USA). Treatment effects for each parameter were determined with one-way analysis of variance and Duncan's Multiple Range Test for mean separation. Statistical significance was considered at p<0.05.

RESULTS

There were no differences in time to first effect (p = 0.06) or lateral recumbency (p = 0.61) among drug treatments (Table 1). However, time to sternal recumbency varied (p = 0.01) by drug treatment (Table 1). Subjectively, the XK deer were lightly sedated and one individual could not be approached, or moved. Three of the four MK deer responded to touch and would have been reactive to invasive procedures during immobilization. All remaining deer were effectively immobilized and unresponsive to touch.

Table 1: Mean signs of immobilization and recovery for 18 captive white-tailed does after administration of immobilizing drugs and appropriate antagonist, 11-13 April 2005, Athens, Georgia

Drug Comb.	Immobilizing drug Dosage mg kg ⁻¹ ±SD	Antagonist dosage mg kg ⁻¹ ±SD	Time to first effect ^a Seconds±SD (n)	Time to sternal recumbency ^a Seconds±SD (n)	Time to lateral recumbency ^a Seconds±SD (n)	Time to head up ^a Seconds±SD (n)	Time to standing ^a Seconds±SD (n)
XK	1.6±0.1 xylazine 7.8±0.3 ketamine	2.1±0.1 tolazoline	215.0±48.0 (3) A	418.7±51.0 (3) A	509.3±32.7 (3) A	82.5±53.0 (2) A	75.0 (1) A
MK	0.075±0.01 medetomidine 2.1±0.2 ketamine	0.37±0.0 atipamezole	184.8±32.5 (4) A	353.0±51.7 (4) AB	497.8±153.0 (4) A	72.5±32.0 (4) A	151.3±33.3 (4) A
MKB	0.072±0.01 medetomidine 2.1±0.2 ketamine 0.1±0.0 butorphanol	0.36±0.0 atipamezole 10.3±1.2 naltrexone	116.3±14.6 (3) A	250.0±14.8 (3) C	546.0±509.3 (3) A	140.0±91.7 (3) A	180.0±120.0 (3) A
MKT-A	0.063±0.0 medetomidine 0.9±0.1 ketamine 2.0±0.1 tiletamine/zolazepam	0.31±0.0 atipamezole	174.5±42.9 (4) A	284.8±57.3 (4) BC	380.0±57.1 (4) A	315.0±241.9 (4) A	620.0±183.3 (3) A
MKT-B	0.067±0.0 medetomidine 1.4±0.1 ketamine 1.1±0.1 tiletamine/zolazepam	0.34±0.0 atipamezole	175.0±34.7 (4) A	275.3±68.0 (4) BC	323.3±69.3 (4) A	510.0±820.5 (4) A	740.0±922.4 (3) A

^aMeans in the same column with different superscripts are significantly different (Time to first effect (p = 0.06), time to sternal (p = 0.01), time to lateral (p = 0.61), time to head up (p = 0.62), time to standing (p = 0.36))

Table 2: Mean values (\pm SD) of physiological parameters for 18 captive white-tailed does after treatment with immobilizing drugs, 11-13 April 2005, Athens, Georgia. Parameters were measured from the time deer were laterally recumbent

Drug Comb. ^a	SpO ₂ $\bar{x} \pm$ SD (n)		Respiration rate breaths/min. $\bar{x} \pm$ SD (n) \pm SD (n)		Heart rate Beats/min. $\bar{x} \pm$ SD (n)		Temperature °C $\bar{x} \pm$ SD (n)	
	20 min.	40 min.	20 min.	40 min.	20 min.	40 min.	20 min.	40 min.
XK ^b	88.0 \pm 8.5(2)	No data	84.0 \pm 87.7 (2)	No data	72.0 \pm 33.9 (2)	No data	42.1 \pm 1.6 (2)	No data
MK ^b	88.3 \pm 8.1 (3)	92.3 \pm 2.9 (3)	27.5 \pm 14.3 (4)	24.7 \pm 11.5 (3)	64.0 \pm 13.9 (4)	60.7 \pm 1.5 (3)	40.3 \pm 1.9 (4)	39.5 \pm 1.0(3)
MKB ^b	86.0 \pm 5.7 (2)	88.0 \pm 4.2 (2)	52.0 \pm 57.2 (3)	14.0 \pm 2.8 (2)	77.3 \pm 28.4 (3)	56.5 \pm 16.3 (2)	41.5 \pm 1.8 (3)	40.2 \pm 1.1(2)
MKT-A	88.3 \pm 6.2 (4)	88.8 \pm 2.2 (4)	33.8 \pm 26.4 (4)	36.5 \pm 26.3 (4)	72.8 \pm 11.0 (4)	63.8 \pm 8.2 (4)	40.2 \pm 0.6 (4)	40.2 \pm 0.6(4)
MKT-B	91.0 \pm 4.8 (4)	91.5 \pm 2.4 (4)	27.0 \pm 11.5 (4)	26.0 \pm 11.7 (4)	66.3 \pm 10.1 (4)	64.3 \pm 11.9 (4)	39.8 \pm 0.5 (4)	39.9 \pm 0.5(4)
p value ^c	0.92	0.23	0.45	0.53	0.87	0.86	0.31	0.63

^aXK = 81 mg Xylazine and 405 mg Ketamine; reversed with 108 mg tolazoline, MK = 3.78 mg Medetomidine and 108 mg Ketamine; reversed with 18.9 mg atipamezole, MKB = 3.78 mg Medetomidine, 108 mg Ketamine, 5.4 mg Butorphanol; reversed with 18.9 mg atipamezole and 540 mg naltrexone, MKT-A = 3.78 mg Medetomidine, 54 mg Ketamine, 118.8 mg Tiletamine/zolazepam; reversed with 18.9 mg atipamezole, MKT-B = 3.78 mg Medetomidine, 81 mg Ketamine, 59.4 mg Tiletamine/zolazepam; reversed with 18.9 mg Atipamezole. ^bSample sizes were reduced because of unapproachable deer or early reversal due to hyperthermia, ^cp value for treatment effects by column

Although not significant, we observed treatment-related trends in physiologic parameters (Table 2). Percent oxygen saturation of hemoglobin was low to within acceptable ranges for all treatment groups (Table 2). Kreeger *et al.* (2002) noted the lack of data on the pathological effects of SpO₂ < 90 and felt the trend was more important. All time points where data was available showed an increase in value and lower variability in SpO₂ at 40 compared to 20 min. Kreeger *et al.* (2002) considered body temperatures > 40°C to represent a state of hyperthermia. Elevated body temperatures were recorded in all treatments groups except the MKT-B. Temperatures were sufficiently elevated to require administration of cold-water enemas in two of three XK, two of three MKB and one of four MK treated deer during the trials. Maximum ambient temperature for Athens, Georgia for each day during our trials was 26, 24 and 18°C (NOAA National Climatic Data Center; <http://cdo.ncdc.noaa.gov/ulck/ULCD>). Because we intervened to lower potentially dangerous body temperatures of some deer, statistical comparisons of post-treatment temperatures were not valid. One previously hyperthermic doe receiving MKB was found dead in the outer pens on 2 May 2005, approximately 3 weeks post drug trial. She appeared healthy the day after treatment. No necropsy was performed due to advanced decomposition of the carcass.

There were no differences among treatments for time to head up and standing after antagonist administration (Table 1). However, two of the three XK deer were reversed early because of hyperthermia. The third XK deer was not approachable and thus not given the antagonist. In the MKB group, two of three deer were reversed early because of hyperthermia. We recorded sedation scores for MK, MKT-A and MKT-B treatments and found no significant differences among these treatments at any point (Fig. 1); however MKT-B qualitatively showed a rapid and predictable reduction in sedation.




Fig. 1: Mean sedation scores of captive white-tailed does after treatment with selected immobilizing drugs and corresponding antagonists, 11-13 April 2005, Athens, Georgia. Deer were given the antagonist (0.35 mg kg⁻¹ atipamezole) 45 min after lateral recumbency. Sedation score of 5 = lateral recumbency with no sign of sedation. Sedation score of 0 = no sign of sedation. There were no differences among drug treatments at any time point

MK = 0.075 mg kg⁻¹ Medetomidine and 2.1 mg kg⁻¹ Ketamine, MKT-A = 0.063 mg kg⁻¹ Medetomidine, 0.9 mg kg⁻¹ Ketamine and 2.0 mg kg⁻¹ tiletamine/zolazepam, MKT-B = 0.067 mg kg⁻¹ Medetomidine, 1.4 mg kg⁻¹ ketamine and 1.1 mg kg⁻¹ Tiletamine/zolazepam.

Because of our daily monitoring of females during the fawning season, we documented neonatal health problems in fawns born to five of 18 treated does. However, one of seven untreated does had an unhealthy fawn as well. The fawns were either stillborn or unthrifty at birth. We were not able to determine if the neonatal health problems were drug or handling related.

DISCUSSION

All treatments except XK effectively immobilized the deer. However, our MK dose did not induce a deep level

of anesthesia. Satisfactory immobilization using a higher dose of MK in mule deer (*O. hemionus*) and mule/white-tailed deer hybrids (0.1 mg kg⁻¹ medetomidine and 2.5 mg kg⁻¹ ketamine) was found (Caulkett *et al.*, 2000). In our study, the addition of butorphanol potentiated the anesthetic effect of MK. However, we do not recommend MKB because of the potential for hyperthermia possibly due to the excitable induction and the high cost of antagonists for this combination. Other opioids have been associated with hyperthermia in white-tailed deer (Miller *et al.*, 2003; Caulkett *et al.*, 2000). The MKB deer that was found dead 3 weeks after the drug trial, was clinically normal prior to her death but exhibited hyperthermia at treatment.

Qualitatively, MKT-A and MKT-B were both effective and relatively safe for chemically immobilizing pregnant deer with sternal recumbency occurring at 4.7±1.0 and 4.6±1.1 min, respectively. Previous research found that mean time to sternal recumbency was 2.4±0.7 for adult female deer treated with xylazine (2.2±0.2 mg kg⁻¹) and tiletamine-zolazepam (4.5±0.4 mg kg⁻¹) (Miller *et al.*, 2004). Although shorter induction times occurred with their xylazine and tiletamine-zolazepam combination, recovery times were extensive. Times to sternal and lateral recumbency are important factors in determining flight distances of deer after darting them in field situations. However, recovery time also is critical when releasing these deer post-capture. Partially anesthetized deer may experience increased risk of predation, intraspecific strife and accidents. Additionally, there is concern for public safety in urban/suburban areas (e.g., deer-vehicle collisions). Therefore, not only induction time, but also recovery time should be considered when deciding on drug protocols for darting deer. The MKT-B group was quickly reversed to minimal sedation after the antagonist was given. Sedation scores of MKT-B were less than MKT-A at 1-5 h after antagonist administration (Fig. 1).

Calculated costs per drug treatment were similar for MK, MKT-A and MKT-B (Table 3). The cost of MKB was

increased greatly by the additional cost of the antagonist, naltrexone. Although XK cost only \$4.86 per dose, it was not effective in immobilizing the deer.

In addition to effectiveness and cost, safety must be a primary consideration. Both MKT-A and MKT-B provided acceptable physiological parameters (Table 2). However, there appeared to be problems with neonatal survival. We do not know whether these problems were due to drug treatments or late-gestation handling stress. DelGiudice *et al.* (1986) found no adverse effects on pregnancy or differences in neonatal survival in does repeatedly given XK during gestation compared to non-immobilized does. Xylazine has been shown to decrease uterine blood flow in pregnant cows (Hodgson *et al.*, 2002). This reduction in flow could potentially result in calf morbidity and/or mortality. At this time, we do not recommend chemically immobilizing late-term pregnant does with our drug protocols.

CONCLUSION

The combination of ketamine (for a relatively shorter recovery time), tiletamine-zolazepam (for rapid induction) and medetomidine (for synergistic effects and increased relaxation) may provide a superior immobilization regimen in white-tailed deer. This study provided preliminary data on the effective and safe use of MKT-A and MKT-B for chemically immobilizing captive deer. Future research should evaluate these drug combinations administered by darting in wild deer.

ACKNOWLEDGMENT

This project was funded by the University of Tennessee, Hatch funding (TEN00228) and the University of Georgia McIntire-Stennis Project (GEO-0126-MS). We are indebted to the help and support of C.H. Killmaster, J.L. Lupardus, W. Parker and J.L. Kindall for assistance with deer immobilizations. We also would like to thank D.L. Miller for consultation and review of an earlier draft.

REFERENCES

- Caulkett, N.A., P.H. Cribb and J.C. Haigh, 2000. Comparative cardiopulmonary effects of carfentanil-xylazine and medetomidine-ketamine use for immobilization of mule deer and mule deer/white-tailed deer hybrids. *Can. J. Vet. Res.*, 64: 64-68.
- Chittick, E., W. Home, B. Wolfe, K. Sladky and M. Loomis, 2001. Cardiopulmonary assessment of medetomidine, ketamine and butorphanol anesthesia in captive Thompson's gazelles (*Gazella thomsoni*). *J. Zoo Wildl. Med.*, 32: 168-175.

Table 3: Cost for chemical immobilization treatments based on a 54 kg deer, 11-13 April 2005, Athens, Georgia

Treatment ^a	Immobilizing drugs (\$)	Antagonist(s) (\$)	Total cost (\$)
XK	4.23	0.63	4.86
MK	16.18	17.77	33.95
MKB	19.15	125.77	144.92
MKT-A	22.95	17.77	40.72
MKT-B	19.56	17.77	37.33

^aXK = 81 mg Xylazine and 405 mg Ketamine; reversed with 108 mg tolazoline, MK = 3.78 mg Medetomidine and 108 mg Ketamine; reversed with 18.9 mg atipamezole, MKB = 3.78 mg Medetomidine, 108 mg Ketamine, 5.4 mg Butorphanol; reversed with 18.9 mg atipamezole and 540 mg naltrexone, MKT-A = 3.78 mg Medetomidine, 54 mg Ketamine, 118.8 mg Tiletamine/zolazepam; reversed with 18.9 mg Atipamezole, MKT-B = 3.78 mg Medetomidine, 81 mg Ketamine, 59.4 mg Tiletamine/zolazepam; reversed with 18.9 mg atipamezole

- Delgiudice, G.D., L.D. Mech, W.J. Paul and P.D. Karns, 1986. Effects of fawn survival of multiple immobilizations of captive pregnant white-tailed deer. *J. Wildl. Dis.*, 22: 245-248.
- Fernández-Morán, J., J. Palomeque and V.I. Peinado, 2000. Medetomidine/tiletamine/zolazepam and xylazine/tiletamine/zolazepam combinations for immobilization of fallow deer (*Cervus dama*). *J. Zoo Wildl. Med.*, 31: 62-64.
- Hodgson, D.S., C.I. Dunlop, P.L. Chapman and J.A. Smith, 2002. Cardiopulmonary effects of xylazine and acepromazine in pregnant cows in late gestation. *Am. J. Vet. Res.*, 63: 1695-1699.
- Jalanka, H.H. and B.O. Roeken, 1990. The use of medetomidine, medetomidine-ketamine combinations and atipamezole in nondomestic mammals: A review. *J. Zoo Wildl. Med.*, 21: 259-282.
- Kreeger, T.J., J.M. Arnemo and J.P. Raath, 2002. Handbook of wildlife chemical immobilization international edition. Wildlife Pharmaceuticals, Fort Collins, Colorado.
- Kilpatrick, H.J. and S.M. Spohr, 1999. Telazol®-xylazine versus ketamine-xylazine: A field evaluation for immobilizing white-tailed deer. *Wildl. Soc. Bull.*, 27: 566-570.
- Kumar, A., H.J. Mann and R.P. Rimmel, 2006. Pharmacokinetics of tiletamine and zolazepam (Telazol®) in anesthetized pigs. *J. Vet. Pharmacol. Therap.*, 29: 587-589.
- Miller, B.F., L.I. Muller, T.N. Storms, E.C. Ramasay, D.A. Osborn, R.J. Warren, K.V. Miller and K.A. Adams, 2003. A comparison of carfentanil/xylazine and telazol®/xylazine for immobilization of white-tailed deer. *J. Wildl. Dis.*, 39: 851-858.
- Miller, B.F., L.I. Muller, T. Doherty, D.A. Osborn, K.V. Miller and R.J. Warren, 2004. Effectiveness of antagonists for tiletamine-zolazepam/xylazine immobilization in female white-tailed deer. *J. Wildl. Dis.*, 40: 533-537.
- Nielson, L., 1999. Chemical immobilization of wild and exotic animals. Iowa State University Press, Ames Iowa.
- Plumb, D.C., 2002. Veterinary drug handbook, (4th Edn.), Iowa State Press, Ames Iowa.
- Wolkers, J., T. Wensing and G.W.T.A. Groot Bruinderink, 1994. Sedation of wild boar (*Sus scrofa*) and red deer (*Cervus elaphus*) with medetomidine and the influence on some haematological and serum biochemical variables. *Vet. Quart.*, 16: 7-9.
- Williams, C.V., K.M. Glenn, J.F. Levine and W.A. Horne, 2003. Comparison of the efficacy and cardiorespiratory effects of medetomidine-based anesthetic protocols in ring-tailed lemurs (*Lemur catta*). *J. Zoo Wildl. Med.*, 34: 163-170.